{
    "eid": "2-s2.0-85097310758",
    "title": "Future of CAR T cells in multiple myeloma",
    "cover-date": "2020-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Kitsada Wudhikarn",
        "Sham Mailankody",
        "Eric L. Smith"
    ],
    "citedby-count": 19,
    "ref-count": 52,
    "ref-list": [
        "Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy",
        "B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma",
        "Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma",
        "JCARH125, anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study (EVOLVE)",
        "Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma",
        "Results from CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (r/r mm)",
        "Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T cell therapy",
        "Long-term follow-up of a phase 1, first-inhuman open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed/refractory multiple myeloma (RRMM)",
        "The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype",
        "International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma",
        "Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis",
        "T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma",
        "B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma",
        "CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape",
        "Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen",
        "GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells",
        "Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma",
        "Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma",
        "A bispecific CAR-T cell therapy targeting Bcma and CD38 for relapsed/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial",
        "A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial",
        "\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma",
        "\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells",
        "Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma",
        "Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells",
        "Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains [published correction appears in Nat Commun. 2020;11(1):1319]",
        "Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector",
        "Targeting the bone marrow microenvironment in multiple myeloma",
        "Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric antigen receptor T cell therapy in multiple myeloma",
        "Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo",
        "Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model",
        "Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment",
        "Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy",
        "CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells",
        "CRISPR-engineered T cells in patients with refractory cancer",
        "Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide",
        "Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma",
        "Therapeutic T cell engineering",
        "Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy",
        "FT576: a novel multiplexed engineered off-the-shelf natural killer cell immunotherapy for the dual-targeting of CD38 and Bcma for the treatment of multiple myeloma",
        "CAR-NK for tumor immunotherapy: clinical transformation and future prospects",
        "T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma",
        "Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia",
        "Chimeric-antigen-receptor (CAR) T cells and the factors influencing their therapeutic efficacy",
        "Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (mm)",
        "Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo",
        "Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011)",
        "Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency [published correction appears in Nat Med. 2019;25(3):530]",
        "Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection",
        "Update of CARTITUDE-1: a phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CART-cell therapy, in relapsed/refractory multiple myeloma",
        "Phase 1 trial of the safety and efficacy of fully human anti-Bcma CAR T cells in relapsed/refractory multiple myeloma",
        "Efficacy and safety of fully human Bcma targeting CAR T cell therapy in relapsed/refractory multiple myeloma"
    ],
    "affiliation": [
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "New York",
            "@id": "60007997",
            "affilname": "Weill Cornell Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60002746",
            "affilname": "Harvard Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002746",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "American Society of Clinical Oncology, Society for Immunotherapy of Cancer",
        "Fate Therapeutics",
        "National Institutes of Health National Cancer Institute",
        "Lymphoma Research Foundation",
        "American Society of Hematology",
        "Leukemia Lymphoma Society",
        "Bristol Myers Squibb",
        "Dana-Farber/Harvard Cancer Center Support",
        "Parker Institute for Cancer Immunotherapy"
    ]
}